Latest Options News

Hot Chili Limited has launched a A$40 million private placement to accelerate development of its Fuego copper project in Costa Rica, issuing shares at a discount to recent prices. The capital raise aims to boost exploration and feasibility studies while enhancing liquidity on the TSX Venture Exchange.

Peak Processing Limited has raised $2.72 million through a discounted share placement to fund growth and operational improvements in its Canadian and US markets. Key directors are backing the raise, signalling confidence in the company’s strategy.

Bellavista Resources has announced a transformative acquisition of a 70% interest in the Pickle Crow Gold Project in Ontario, Canada, alongside a A$25 million equity raise to fund exploration and development.

Bellavista Resources Ltd has agreed to acquire a majority stake in the high-grade Pickle Crow Gold Project in Ontario, Canada, boasting a 2.8 million ounce inferred resource at 7.2g/t gold. The company is also raising up to A$25 million to fund aggressive exploration and development.

Bellavista Resources Ltd has agreed to acquire up to 80% of the Pickle Crow Gold Project in Ontario, Canada, adding a 2.8 million ounce inferred gold resource at 7.2g/t to its portfolio. The company is raising A$25 million to fund aggressive exploration and development activities.

Estrella Resources has entered a $2 million underwriting agreement to support the exercise of its listed options, ensuring capital inflow ahead of the December expiry.

Arcadia Minerals has secured a binding term sheet with Hongkong Xinhai Mining Services, granting Xinhai an exclusive option to advance the Swanson Tantalum Project in Namibia towards production through a strategic partnership and investment.

First Au Limited has successfully raised $5.6 million in a placement to fund exploration at its Gimlet Gold Project and expand its Western Australian gold strategy.

First Au Limited has reported strong initial assay results from its Phase 3 drilling at the Gimlet Gold Project, confirming high-grade gold mineralisation and setting the stage for a resource upgrade.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.